Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news

Subscribe to Pharma in Focus

Sign Up Now

Pharma in Focus is considered essential daily reading in the Australian and NZ pharma industry.

In production for 12 years, it is emailed daily to more than 10,000 pharma industry professionals throughout Australia and NZ.

For just $429.95 a year (plus GST) Pharma in Focus puts you ahead of the game by delivering:

  • Key Aussie & NZ pharma news every working day
  • Daily in-depth features covering all aspects of pharma from drug approvals to employment issues
  • Full coverage and analysis of PBAC, PBS and TGA decisions
  • Ten survey-based white papers per year (total value $1500)

New to Pharma in Focus? Sign up below for your FREE two week trial.

Time to subscribe? Sign up below for your 12 month subscription.

Need multiple licenses? We have great corporate rates. Contact our friendly subscription managers on 02 9939 1881 or admin@pharmainfocus.com.au for our latest prices.

3 Simple Steps

1 Fill in your details below and submit

2 Make your subscription choice

3 Make your payment choice (Credit Card, Direct Deposit or Cheque)

Perspective
What's the King review think it's doing?
Is the King review sending industry a message that disruptive reform of the PBS is anything but over despite MA's agreement with government?
Approvals Action
First threat to $63m pain drug
Sandoz's new generic competitor could make a serious hole in the drug that represents close to 40 per cent of Mundipharma's total PBS earnings.
Pipeline Monitor
FDA issues flood of approvals
The US regulatory body issued a number of approvals this week including a new combination use for Janssen's oncology med Darzalex and two ADHD meds.